Immunosuppressant withdrawal versus glucocorticoid withdrawal in SLE: 2-year outcomes of a noninferiority randomized controlled trial
- 24 March 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4283-4291
Abstract
Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.Keywords
Funding Information
- Jawaharlal Institute Of Postgraduate Medical Education and Research (JIP/Res/intramural/subcom/2020-2021)
This publication has 37 references indexed in Scilit:
- Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus ErythematosusACR Open Rheumatology, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centreClinical Rheumatology, 2018
- A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapyKidney International, 2018
- Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper PatientsArthritis Care & Research, 2017
- The global burden of SLE: prevalence, health disparities and socioeconomic impactNature Reviews Rheumatology, 2016
- Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus CohortArthritis & Rheumatism, 2012
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996